Advert for £49 serum banned over ‘five years younger’ claim

Regulatory scrutiny targets skin rejuvenation claims

Advert for 49 serum banned over – A promotional display for a £49 face serum has been revoked by the Advertising Standards Authority (ASA) following allegations of deceptive advertising. The product in question, Eucerin Hyaluron-Filler Epigenetic Serum, was advertised with the assertion that it could make users appear up to five years younger. This claim, made through a billboard poster at London’s Balham Tube station, drew a single complaint in November 2025. The ASA’s investigation revealed significant issues with the evidence provided to substantiate the assertion, leading to the ad’s prohibition.

Study methodology under fire

The central claim of the advertisement hinged on a study involving 160 participants who used the serum for four weeks before evaluating their perceived age reduction. According to the ad, the serum was “clinically proven” to yield results. However, the ASA expressed skepticism about the study’s reliability, citing methodological flaws. One major concern was the absence of a control group—individuals who did not use the product—to compare outcomes. Additionally, the watchdog highlighted the lack of transparency regarding how participants were selected, raising doubts about the representativeness of the sample.

Self-reported results questioned

The ASA emphasized that the study relied heavily on self-reported data, which can be subjective and influenced by personal biases. Without objective measures, the assessment of “looking five years younger” became open to interpretation. Beiersdorf, the manufacturer, defended its claim by stating that the phrase “up to five years younger” was intended to reflect the maximum possible outcome, rather than a guaranteed or average result. The company argued that the assertion was not an absolute promise but a realistic ceiling based on the study’s findings.

Environmental factors and unpublished research

The ASA further noted that the study was conducted in a climate different from the UK, suggesting the product’s effectiveness might not translate consistently to local conditions. This discrepancy added to the skepticism surrounding the claim. In addition to the primary study, Beiersdorf submitted three supplementary pieces of evidence to support its advertising. However, all of these were unpublished research, which the watchdog found questionable. The lack of peer-reviewed validation for these studies weakened their credibility.

Peer-reviewed study excludes the serum

Despite these challenges, Beiersdorf presented one final piece of evidence—a peer-reviewed study examining the active ingredient in the serum. The ASA, however, pointed out that this study did not include the specific product being advertised. This omission left the core claim without robust scientific backing, as the peer-reviewed research focused on the ingredient rather than the complete formulation. The company maintained that its studies adhered to industry standards, but the ASA’s findings underscored the need for more rigorous validation.

Industry standards and consumer trust

The ban highlights broader issues in cosmetics advertising, where companies often rely on limited data to make impactful claims. Lianne Sykes, an aesthetics marketing expert who advises firms on ethical advertising, criticized the trend of using vague or overstated assertions without thorough substantiation. “Consumers are bombarded with promises like ‘instant results’ or ‘five years younger,’ but these claims rarely have solid evidence,” Sykes stated. She stressed that effective advertising should account for variables such as skin type, lifestyle factors, and environmental influences.

Call for long-term analysis and transparency

Sykes advocated for companies to conduct extended skin analysis over months or even years, rather than relying on short-term trials. “A single study of four weeks is insufficient to prove a dramatic effect like age reduction,” she explained. She also urged advertisers to clarify the conditions under which results were measured, such as whether participants were monitored in controlled environments or exposed to real-world factors. “Without this detail, consumers can’t fully understand what they’re being promised,” Sykes added.

Consumer awareness and habit-based outcomes

The expert emphasized that individual skin biology varies widely, and many people achieve good skin health through consistent routines rather than a single product. “Firms should not assume that a branded item alone will deliver miraculous results,” Sykes cautioned. She recommended that consumers question the validity of claims by asking about testing methodologies, sample diversity, and whether results were measured using standardized tools. “Even the most reputable names can mislead if their evidence is weak,” she warned.

Beiersdorf’s response and future implications

In response to the ASA’s decision, Beiersdorf reiterated that its products were “supported by scientific research.” The company stated that the billboard ad was no longer active in the UK and that it had taken the findings seriously. However, the ASA’s ruling serves as a reminder of the importance of rigorous testing and clear communication in advertising. The case also raises questions about the adequacy of current industry standards, particularly when claims are as bold as those made for the Eucerin serum.

Regulatory evolution and consumer expectations

As cosmetics advertising becomes more competitive, the pressure to make compelling claims increases. This has led to a growing reliance on studies that may not fully capture the product’s impact. Sykes believes that regulatory bodies must adapt to ensure advertisers meet higher benchmarks. “The standards need to evolve to reflect modern consumer expectations,” she said. “People want tangible proof, not just glossy branding.”

Looking ahead: Balancing innovation and accuracy

The Eucerin case is part of a larger trend where companies push the boundaries of what can be scientifically proven. While innovation in skincare is commendable, the ASA’s intervention underscores the necessity of evidence-based claims. Sykes suggested that advertisers should invest in comprehensive research, including cross-cultural studies and long-term trials, to build credibility. “The goal is not just to sell a product but to earn trust,” she said.

Key takeaways for the industry

For businesses in the cosmetics sector, the ban serves as a cautionary tale. It emphasizes the importance of transparency in advertising and the need for studies that account for real-world conditions. The ASA’s report also highlighted the role of self-reporting in introducing subjectivity, a common pitfall in consumer-centric claims. As the industry continues to grow, maintaining a balance between marketing creativity and scientific accuracy will be critical.

Consumer advocacy and informed decision-making

In addition to regulatory oversight, Sykes called for greater consumer awareness. She urged individuals to scrutinize advertisements critically, asking questions about the study’s design, sample size, and outcome measurement. “Consumers should not take marketing claims at face value,” Sykes said. “They need to understand the evidence behind each promise.” By fostering a culture of informed decision-making, both regulators and companies can work toward more trustworthy advertising.

Final thoughts on the case

The Eucerin serum’s banned advertisement is a prime example of how even well-intentioned claims can fall short of scientific rigor. While the company maintains that its research aligns with industry norms, the ASA’s scrutiny reveals gaps in how evidence is presented. This case could set a precedent for future advertising standards, ensuring that products making bold claims are backed by thorough, reproducible data. As Sykes noted, the cosmetics industry must prioritize transparency to sustain consumer confidence.

Newsletter sign-up for daily headlines

Stay updated with the latest news and insights by subscribing to our flagship newsletter. It delivers all the essential headlines you need to start your day. Sign up here to receive regular updates.